Andre Filipe Afonso de Sousa Fonseca

Dr. Andre Filipe Afonso de Sousa Fonseca

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2024 in Medicina
Verified
Journal Article
Open access
PDF file
AFAndre Filipe Afonso de Sousa Fonseca
Andre Filipe Afonso de Sousa Fonseca
MSMateusz Szysz
Mateusz Szysz
HLHoang Thien Ly
Hoang Thien Ly
CCClara Cordeiro
Clara Cordeiro
NSNuno Sepúlveda
Nuno Sepúlveda
Background and Objectives: The diagnosis and pathology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) remain under debate. However, there is a growing body of evidence for an autoimmune component in ME/CFS caused by the Epstein-Barr virus (EBV) and other viral infections. Materials and Methods: In this work, we analyzed a large public dataset on the IgG antibodies to 3054 EBV peptides to understand whether these immune responses could help diagnose patients and trigger pathological autoimmunity; we used healthy controls (HCs) as a comparator cohort. Subsequently, we aimed at predicting the disease status of the study participants using a super learner algorithm targeting an accuracy of 85% when splitting data into train and test datasets. Results: When we compared the data of all ME/CFS patients or the data of a subgroup of those patients with non-infectious or unknown disease triggers to the data of the HC, we could not find an antibody-based classifier that would meet the desired accuracy in the test dataset. However, we could identify a 26-antibody classifier that could distinguish ME/CFS patients with an infectious disease trigger from the HCs with 100% and 90% accuracies in the train and test sets, respectively. We finally performed a bioinformatic analysis of the EBV peptides associated with these 26 antibodies. We found no correlation between the importance metric of the selected antibodies in the classifier and the maximal sequence homology between human proteins and each EBV peptide recognized by these antibodies. Conclusions: In conclusion, these 26 antibodies against EBV have an effective potential for disease diagnosis in a subset of patients. However, the peptides associated with these antibodies are less likely to induce autoimmune B-cell responses that could explain the pathogenesis of ME/CFS.

25 April 2022 in medRxiv
Verified
Preprint
Open access
PDF file
NSNuno Sepúlveda
Nuno Sepúlveda
JMJoao Malato
Joao Malato
FSFranziska Sotzny
Franziska Sotzny
AGAnna Daria Grabowska
Anna Daria Grabowska
AFAndre Filipe Afonso de Sousa Fonseca
Andre Filipe Afonso de Sousa Fonseca
CSCarmen Scheibenbogen
Carmen Scheibenbogen
Infections by the Epstein-Barr virus (EBV) are often at the disease onset of patients suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). However, serological analyses of these infections remain inconclusive when comparing patients with healthy controls. In particular, it is unclear if certain EBV-derived antigens eliciting antibody responses have a biomarker potential for disease diagnosis. With this purpose, we re-analysed a previously published microarray data on the IgG antibody responses against 3,054 EBV-related antigens in 92 patients with ME/CFS and 50 HCs. This re-analysis consisted of constructing different regression models for binary outcomes with the ability to classify patients and HCs. In these models, we tested for a possible interaction of different antibodies with age and gender. When analyzing the whole data set, there were no antibody responses that could be used to distinguish patients from healthy controls. A similar finding was obtained when comparing patients with noninfectious or unknown disease trigger to healthy controls. However, when data analysis was restricted to the comparison between HCs and patients with a putative infection at disease onset, we could identify stronger antibody responses against two candidate antigens (EBNA4_0529 and EBNA6_0070). Using antibody responses to these two antigens together with age and gender, the final classification model had an estimated sensitivity and specificity of 0.833 and 0.720, respectively. This reliable case-control discrimination suggested the use of the antibody levels related to these candidate viral epitopes as biomarkers for disease diagnosis in this subgroup of patients. When a bioinformatic analysis was performed on these epitopes, it revealed a potential molecular mimicry with several human proteins. To confirm these promising findings, a follow-up study will be conducted in a separate cohort of patients.


7 October 2022 in medRxiv
Verified
Preprint
Open access
PDF file
AFAndre Filipe Afonso de Sousa Fonseca
Andre Filipe Afonso de Sousa Fonseca
MSMikolaj Spytek
Mikolaj Spytek
PBPrzemyslaw Biecek
Przemyslaw Biecek
CCClara Cordeiro
Clara Cordeiro
NSNuno Sepúlveda
Nuno Sepúlveda
Background: Nowadays, the chance of discovering the best antibody candidates for explaining naturally acquired protection to malaria and detecting exposure to malaria parasites has notably increased due to publicly available multi-sera data. The analysis of these data is typically divided into a feature selection phase followed by a predictive one where several models are constructed for the outcome of interest. A key question in the analysis is to determine which and how each feature should be included in the predictive stage. Results: To answer this question, we developed three approaches for classifying malaria protected and susceptible groups: (i) a basic and simple approach based on selecting antibodies via the nonparametric Mann-Whitney test; (ii) a dichotomization approach where each antibody was selected according to the optimal cut-off via maximization of the χ 2 statistic for two-way tables; (iii) a hybrid parametric/non-parametric approach that integrates Box-Cox transformation followed by a t-test, together with the use of finite mixture models and the Mann-Whitney test as a last resort. We illustrated the application of these three approaches with published serological data for predicting clinical malaria in 121 Kenyan children. The predictive analysis was based on a Super-Learner where predictions from multiple classifiers were pooled together. Our results led to almost similar areas under the Receiver Operating Characteristic curves of 0.72 (95% CI = [0.61, 0.82]), 0.80 (95% CI = [0.71, 0.90]), 0.79 (95% CI = [0.7, 0.88]) for the simple, dichotomization and hybrid approaches, respectively. Conclusions: The three feature selection strategies provided a better predictive performance of the outcome when compared to the previous results solely relying on Random Forests alone (AUC=0.68). Given the similar predictive performance, we recommended the three strategies should be used in conjunction in the same data set and selected according to their complexity.

23 November 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
AFAndre Filipe Afonso de Sousa Fonseca
Andre Filipe Afonso de Sousa Fonseca
MSMateusz Szysz
Mateusz Szysz
HLHoang Thien Ly
Hoang Thien Ly
CCClara Cordeiro
Clara Cordeiro
NSNuno Sepúlveda
Nuno Sepúlveda
The diagnosis and the pathology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) remain under debate. However, there is a growing body of evidence for an autoimmune component in ME/CFS caused by the Epstein-Barr virus (EBV) and other viral infections. In this work, we took advantage of a large public dataset on the IgG antibodies to 3,054 EBV peptides to understand whether these immune responses could be used as putative biomarkers for disease diagnosis and triggers of pathological autoimmunity in ME/CFS patients using healthy controls (HCs) as a comparator cohort. We then aimed at predicting disease status of study participants using a Super Learner algorithm targeting an accuracy of 85% when splitting data into train and test datasets. When we compared data of all ME/CFS patients or data of a subgroup of these patients with non-infectious or unknown disease trigger to the dataset of HC, we could not find an antibody-based classifier that would meet the desired accuracy in the test dataset. In contrast, we could identify a 26-antibody classifier that could distinguish ME/CFS patients with an infectious disease trigger from HCs with 100% and 90% accuracies on the train and test sets, respectively. We finally performed a bioinformatic analysis of the EBV peptides associated with these 26 antibodies. We found no correlation between the importance metric of the selected antibodies in the classifier and the maximal sequence homology between human proteins and each EBV peptide recognized by these antibodies. In conclusion, these 26 antibodies against EBV have an effective potential for disease diagnosis of a subset of patients, but they are less likely to trigger pathological autoimmune responses that could explain the pathogenesis of ME/CFS.

24 March 2021 in medRxiv
Verified
Preprint
Open access
PDF file
JMJoao Malato
Joao Malato
FSFranziska Sotzny
Franziska Sotzny
SBSandra Bauer
Sandra Bauer
HFHelma Freitag
Helma Freitag
AFAndre Filipe Afonso de Sousa Fonseca
Andre Filipe Afonso de Sousa Fonseca
NSNuno Sepúlveda
Nuno Sepúlveda
Patients affected by Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) show specific epigenetic and gene expression signatures of the disease. However, it is unknown whether these signatures include abnormal levels of the human angiotensin-converting enzymes, ACE and ACE2, the latter being the main receptor described for the host-cell invasion by SARS-CoV-2. To investigate that, we first re-analyzed available case-control epigenome-wide association studies based on DNA methylation data, and case-control gene expression studies based on microarray data. From these published studies, we found an association between ME/CFS and 4 potentially hypomethylated probes located in the ACE locus. We also found another disease association with one hypomethylated probe located in the transcription start site of ACE2. The same disease associations were obtained for women but not for men after performing sex-specific analyses. In contrast, a meta-analysis of gene expression levels could not provide evidence for a differentially expression of ACE and ACE2 in affected patients when compared to healthy controls. In line with this negative finding, the analysis of a new data set on the gene expression of ACE and ACE2 in peripheral blood mononuclear cells did not find any differences between a female cohort of 37 patients and 34 age-matched healthy controls. Future studies should be conducted to extend this investigation to other potential receptors used by SARS-CoV-2. These studies will help researchers and clinicians to improve the understanding of the health risk imposed by this virus when infecting patients affected by this debilitating disease.